EUR 0.87
(-3.89%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | -12.13 Million EUR | -70.7% |
2022 | -7.79 Million EUR | -934.93% |
2021 | -753 Thousand EUR | -115.98% |
2020 | 4.71 Million EUR | 60.44% |
2019 | 2.93 Million EUR | 20.02% |
2018 | 2.44 Million EUR | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 Q1 | -828 Thousand EUR | 79.65% |
2024 Q2 | -1.07 Million EUR | -29.35% |
2024 Q3 | -2.1 Million EUR | -96.83% |
2023 FY | -13.3 Million EUR | -70.7% |
2023 Q4 | -4.06 Million EUR | 0.0% |
2023 Q1 | -1.9 Million EUR | 11.73% |
2023 Q3 | -4.06 Million EUR | -94.18% |
2023 Q2 | -2.09 Million EUR | -10.09% |
2022 Q3 | -2.15 Million EUR | 17.43% |
2022 Q4 | -2.15 Million EUR | 0.0% |
2022 FY | -7.79 Million EUR | -934.93% |
2022 Q2 | -2.61 Million EUR | -50.01% |
2022 Q1 | -1.74 Million EUR | 57.29% |
2021 Q4 | -4.07 Million EUR | -669.13% |
2021 FY | -753 Thousand EUR | -115.98% |
2021 Q3 | 716 Thousand EUR | -51.69% |
2021 Q2 | 1.48 Million EUR | 13.78% |
2021 Q1 | 1.3 Million EUR | -48.09% |
2020 Q3 | 638 Thousand EUR | 0.0% |
2020 FY | 4.71 Million EUR | 60.44% |
2020 Q4 | 2.5 Million EUR | 293.26% |
2019 FY | 2.93 Million EUR | 20.02% |
2018 FY | 2.44 Million EUR | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
BBS-Bioactive Bone Substitutes Oyj | -3.36 Million EUR | -260.356% |
Nexstim Plc | -1.19 Million EUR | -916.554% |
Revenio Group Oyj | 26.34 Million EUR | 146.054% |